Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer

被引：67
|
作者：
Mbeutcha, Aurelie [1 ,2 ]
Lucca, Ilaria [1 ,3 ]
Mathieu, Romain [1 ,4 ]
Lotan, Yair [5 ]
Shariat, Shahrokh F. [1 ,5 ,6 ]
机构：
[1] Med Univ Vienna, Vienna Gen Hosp, Ctr Comprehens Canc, Dept Urol, A-1090 Vienna, Austria
[2] Univ Nice Sophia Antipolis, CHU Nice, Hop Archet 2, Dept Urol, F-06200 Nice, France
[3] CHU Vaudois, Dept Urol, CH-1010 Lausanne, Switzerland
[4] Rennes Univ Hosp, Dept Urol, F-35000 Rennes, France
[5] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75235 USA
[6] Cornell Univ, Weill Cornell Med Coll, Dept Urol, New York, NY 10011 USA
来源：
UROLOGIC CLINICS OF NORTH AMERICA | 2016年 / 43卷 / 01期
关键词：
TRANSITIONAL-CELL CARCINOMA; IN-SITU HYBRIDIZATION; COMPLEMENT FACTOR-H; NUCLEAR-MATRIX PROTEIN-22; INVASIVE UROTHELIAL CARCINOMA; TRANSCRIPTASE MESSENGER-RNA; POLYMERASE-CHAIN-REACTION; PRIMARY-CARE PHYSICIANS; VOIDED-URINE; FOLLOW-UP;
D O I：
10.1016/j.ucl.2015.08.005
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The standard of care for detection and surveillance of bladder cancer consists of cytology and cystoscopy, but both examinations suffer from many limitations, including issues related to accuracy, invasiveness, and cost. Several noninvasive methods for detection and surveillance of bladder cancer have been developed and urine-based biomarkers seem the most promising. This nonsystematic review critically analyzes the commercially available biomarkers and highlights some upcoming investigational biomarkers. To date, none of these biomarkers has sufficient validation to serve as a reliable alternative to cystoscopy.
引用
收藏
页码：47 / +
页数：17
相关论文
共 50 条
  • [1] Use of Urinary Biomarkers in Cancer of the Bladder: Current Status
    Nerli, Rajendra B.
    Ghagane, Shridhar C.
    Pujar, Sanjay Vijay
    Rangrez, Shadab Sadiq
    JOURNAL OF THE SCIENTIFIC SOCIETY, 2019, 46 (02) : 37 - 40
  • [2] Current status of genetic urinary biomarkers for surveillance of non-muscle invasive bladder cancer: a systematic review
    Lozano, F.
    Raventos, C. X.
    Carrion, A.
    Trilla, E.
    Morote, J.
    BMC UROLOGY, 2020, 20 (01)
  • [3] Current status of genetic urinary biomarkers for surveillance of non-muscle invasive bladder cancer: a systematic review
    F. Lozano
    C. X. Raventos
    A. Carrion
    E. Trilla
    J. Morote
    BMC Urology, 20
  • [4] Current and Emerging Bladder Cancer Urinary Biomarkers
    Parker, Justin
    Spiess, Philippe E.
    THESCIENTIFICWORLDJOURNAL, 2011, 11 : 1103 - 1112
  • [5] Urinary biomarkers of nonmuscle-invasive bladder cancer: current status and future potential
    Calistri, Daniele
    Casadio, Valentina
    Bravaccini, Sara
    Zoli, Wainer
    Amadori, Dino
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (06) : 743 - 752
  • [6] Use of urinary biomarkers for bladder cancer surveillance: Patient perspectives
    Yossepowitch, Ofer
    Herr, Harry W.
    Donat, S. Machele
    JOURNAL OF UROLOGY, 2007, 177 (04): : 1277 - 1282
  • [7] Advances in Biomarkers for Detection, Surveillance, and Prognosis of Bladder Cancer
    Henning, Grant M.
    Barashi, Nimrod S.
    Smith, Zachary L.
    CLINICAL GENITOURINARY CANCER, 2021, 19 (03) : 194 - 198
  • [8] Can urinary biomarkers replace cystoscopic examination in bladder cancer surveillance?
    Yutkin, Vladimir
    Nisman, Benjamin
    Pode, Dov
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (06) : 787 - 790
  • [9] Current status of urinary diagnostic biomarkers for colorectal cancer
    Iwasaki, Hiroyasu
    Shimura, Takaya
    Kataoka, Hiromi
    CLINICA CHIMICA ACTA, 2019, 498 : 76 - 83
  • [10] The role of radiotherapy in urinary bladder cancer: current status
    Marta, Gustavo Nader
    Hanna, Samir Abdallah
    Gadia, Rafael
    Miranda Correa, Sebastiao Francisco
    Fernandes da Silva, Joao Luis
    Carvalho, Heloisa de Andrade
    INTERNATIONAL BRAZ J UROL, 2012, 38 (02): : 144 - 153
12345